DELBERT-LABORATORIES
DELBERT Laboratories are proud to announce the acquisition from Noventia Pharma Srl of the European MA of CEPLENE® 0.5mg/0.5ml, solution for injection (histamine dihydrochloride) on September 12, 2022, and strengthens its commitment in hematology-oncology in Europe.
Ceplene® demonstrated a clinical interest in maintenance treatment of acute myeloid leukemia (AML) in patients below 60 years of age in first "complete remission" (symptom-free period of disease after initial treatment) in a clinical study published in Blood in 2006 and received orphan drug designation in 2005 1,2,3.
Acute myeloid leukemias are rare genetic diseases. In Europe, the incidence is estimated at 3.7/100,000 new cases per year. The prognosis for AML is unfavourable with a 5-year relative survival rate of 19%4.
DELBERT Laboratories (https://laboratoires-delbert.fr/) is a French pharmaceutical company specialized in the "renewal of essential medicines" frequently affected by marketing termination, stock shortages, particularly in times of crisis.
"We are focused on keeping essential medicines available to patients in 3 therapeutic areas (Antiinfectives, CNS and Oncology), with the mission of maintaining the therapeutic arsenal of doctors and preventing well-balanced patients from changing treatments.The acquisition of Ceplene's® MA in Europe is part of this strategy to maintain essential medicines and make available medicines with clinical benefit in rare diseases," said Eric Fidelin (Head of Strategy & Global Development).
With this acquisition, DELBERT Laboratories strengthens its presence in hematological oncology.
About DELBERT Laboratories
The mission of DELBERT Laboratories is to maintain access to Drugs of Major Therapeutic Interest for patients. Every year, Delbert Laboratories acquires new drugs whose future is compromised.
DELBERT Laboratories focuses its efforts on finding production sites in Europe. With their collaborators and the support of clinicians, galenicians, engineers and chemists, DELBERT Laboratories are reviving these drugs in order to guarantee their availability to the medical profession and patients.
DELBERT Laboratories will reach more than €30m in turnover in 2022 with double-digit growth each year and already markets 14 products (including 13 originators) with hospital or specialists reserved prescriptions.
DELBERT Laboratories financed this acquisition thanks to trusting relationships with their financial partners who strongly support these values focused on patient access to Drugs of Major Therapeutic Interest.
http://www.laboratoires-delbert.fr/
References:
1. Brune et al., Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial Blood, 1 july 2006 volume 108, number 1, 88-96
2. Nilsson, Malin S., et al. Complete remission after the first cycle of induction chemotherapy determines the clinical efficacy of relapse‐preventive immunotherapy in acute myeloid leukaemia. British Journal of Haematology 188.4 (2020): e49
3. Ceplene® Epar, 2008 - EMEA/H/C/000796
4. Visser et al. Incidence, survival and prevalence of myeloid malignancies in Europe. Eur J Cancer 2012 Nov;48(17):3257-66.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221116005760/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Guardant Health and Policlinico Gemelli Launch In-House Liquid Biopsy Testing Service in Italy9.12.2025 14:05:00 CET | Press release
Leading European Hospital System Begins Offering On-site Liquid Biopsy Testing Based on Proprietary Guardant360® CDx Technology Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the successful launch of FPG 360, an in-house liquid biopsy testing service at the Fondazione Policlinico Universitario Agostino Gemelli IRCCS (Policlinico Gemelli) in Rome, Italy. This partnership is the latest in a series of public-private partnerships Guardant Health has formed with top-tier European academic and research hospitals that embed its groundbreaking technology with existing care pathways to expand access to more cancer patients. Policlinico Gemelli will offer on-site liquid biopsy testing based on Guardant360® CDx technology. The collaboration expands access to precision oncology diagnostics and supports both routine care and clinical research. FPG 360 is one of the first dedicated liquid biopsy testing facilities in Italy housed within a hospital system. P
NTT DATA appoints CEO of newly established AI Company NTT DATA AIVista, Inc.9.12.2025 14:00:00 CET | Press release
Dr. Bratin Saha joins NTT DATA AIVista, Inc., bringing extensive experience in AI, infrastructure, platforms and solutions NTT DATA AIVista, Inc. established in Silicon Valley to help NTT operating companies accelerate the launch and scaling of AI native businesses NTT DATA, a global leader in AI, digital business and technology services, today announced the appointment of Dr. Bratin Saha as CEO of the newly established AI Company, NTT DATA AIVista, Inc., effective Dec 1, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251209189202/en/ Dr. Bratin Saha, newly appointed CEO of NTT DATA AIVista, Inc. Saha brings deep expertise in AI, infrastructure, platforms and solutions; scaling new businesses and significant ecosystem relationships. Prior to joining NTT DATA, he held executive positions at NVIDIA, Amazon Web Services (AWS) and most recently DigitalOcean. At NVIDIA, Saha served as Vice President of Software Infrastructu
Aqemia to Attend the 44th Annual J.P. Morgan Healthcare Conference 20269.12.2025 14:00:00 CET | Press release
Aqemia, a drug invention company combining generative AI and quantum-inspired physics, announces it will attend and hold 1x1 meetings at the 44th Annual J.P. Morgan Healthcare Conference, taking place at The Westin St. Francis in San Francisco from January 12 to 15, 2026. Aqemia will be represented by Maximilien Levesque, CEO and co-founder, Emmanuelle Martiano, COO and co-founder, and Théa Vu-Bignand, VP Finance. Powered by QEMI, its proprietary physics-based generative AI engine for therapeutic molecule invention, Aqemia designs novel drug candidates in a repeatable, efficient, and scalable way. The company focuses on advancing its internal preclinical pipeline while establishing partnerships that validate its platform and scientific differentiation, with the ambition to accelerate the delivery of new therapies in areas of high unmet medical need. About Aqemia Aqemia is a drug invention company dedicated to creating novel molecules to address unmet medical needs. Its proprietary QEMI
Avia Expands to Europe with New German Subsidiary9.12.2025 14:00:00 CET | Press release
AviaGames, a leading global mobile skill-based gaming platform, today announced the establishment of a new subsidiary in Germany. Games industry veteran Michelle Zou has been appointed to head the new entity, overseeing market expansion and investment initiatives across Europe. This move marks a significant milestone in AviaGames’ global growth strategy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251209920028/en/ Games industry veteran Michelle Zou has been appointed to head the AviaGames German subsidiary, overseeing market expansion and investment initiatives across Europe. AviaGames has rapidly emerged as one of the most prominent interactive entertainment companies worldwide, with a global user base of tens of millions of players across North America, and Europe, spanning North America and beyond. The company is especially recognized for its popularity among female players and for delivering high-quality, skill-based
ExaGrid Wins 3 New Industry Awards at the MSP Channel Awards9.12.2025 14:00:00 CET | Press release
Awards highlight ExaGrid’s achievements in the MSP sector ExaGrid®, the industry’s only Tiered Backup Storage solution with AI-Powered Retention Time-Lock (RTL) that includes a non-network-facing tier (tiered air gap), Auto Detect & Guard, delayed deletes and immutability for ransomware recovery, today announced that the company was honored with three awards during the 1st annual MSP Channel Awards ceremony, held in London on December 3, 2025, including: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251209577454/en/ Photo courtesy of MSP Channel Awards. Backup & DR Innovation of the Year Storage Hardware Innovation of the Year Storage Vendor of the Year Many Managed Service Providers (MSPs) use ExaGrid Tiered Backup Storage to offer their customers Backup as a Service (BaaS), Disaster Recovery as a Service (DRaaS), and IT Data Center Outsourcing. In 2025, ExaGrid released new features that help MSPs track their customers’ d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom